TWST

TWST

USD

Twist Bioscience Corporation Common Stock

$40.110+0.390 (0.982%)

即時價格

Healthcare
Diagnostics & Research
美國

價格圖表

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$39.720

最高

$40.590

最低

$39.060

交易量

0.11M

公司基本面

市值

2.4B

行業

Diagnostics & Research

國家

United States

交易統計

平均交易量

1.17M

交易所

NMS

貨幣

USD

52週範圍

最低 $30.32當前 $40.110最高 $60.9

AI分析報告

最後更新: 2025年4月22日
由AI生成數據來源: Yahoo Finance, Bloomberg, SEC

TWST (Twist Bioscience Corporation Common Stock): What's Happening and What to Watch

Stock Symbol: TWST Generate Date: 2025-04-22 20:53:32

Alright, let's break down what's been going on with Twist Bioscience stock and what the tea leaves might be suggesting. We'll look at the latest news, how the price has been acting, and what some of the automated tools are predicting.

The Latest News Buzz

So, the main piece of news we've got is from Barclays, a pretty big bank. Their analyst, Luke Sergott, still thinks Twist Bioscience is a stock you should probably hold onto – they kept their "Overweight" rating. That's generally a good sign; it means they see potential here.

But, and this is a key point, they did lower their price target. They used to think the stock could hit $58, but now they're saying $45. What does that tell us? It's a bit of a mixed signal. They haven't given up on the company, which is positive. However, they're less optimistic about just how much it's likely to climb in the near future. Think of it like a coach still believing in the team but maybe adjusting their expectations for the next few games.

Checking the Price Action

Looking at the stock's journey over the past couple of months, it's been quite a ride. Back in late January and early February, shares were trading up in the $50-$55 range. Things took a noticeable dip through February and into early March, dropping into the high $30s and low $40s. March saw a bit of a bounce, getting back into the mid-$40s briefly.

More recently, in April, we saw another slide, with the price hitting lows around $33-$34. As of the last data point (April 22nd), the stock closed around $36.94. So, the overall trend from the start of the year has been downwards, but it seems to have found some sort of floor in the mid-$30s lately.

Now, let's peek at what the AI prediction model is saying for the very short term. It predicts the price will be essentially flat today (0.0% change), but then sees a potential upward move of about 4% tomorrow and another 4% the day after. That suggests the AI thinks this recent stability in the mid-$30s could be a springboard for a small bounce.

Putting It All Together: What Might Be Next?

Based on the news, the recent price moves, and the AI's short-term forecast, here's one way to look at it:

The analyst still likes the stock overall, even with a lower target. The price has taken a hit but seems to be trying to stabilize around the mid-$30s. The AI model is actually predicting a small upward push from here in the next couple of days.

This combination might suggest a cautiously positive leaning for the very near term. It doesn't scream "buy everything now," but it doesn't necessarily say "run for the hills" either.

  • Potential Entry Consideration: If you were thinking about this stock, the current price area in the mid-$30s, especially if it dips back towards those recent lows around $34, could be a point of interest. This aligns with where the AI sees a potential bounce starting.
  • Potential Exit/Stop-Loss Consideration: Managing risk is always smart. The recommendation data points to $31.08 as a potential stop-loss level. This is below the recent lows and could be a place to consider cutting losses if the price breaks down significantly. For taking profits, the analyst's new target of $45 is out there as a longer-term goal. For the very short term, if the AI's prediction plays out, you might look for a move towards the upper end of the recent range, perhaps the low $40s, but that's just speculation based on past volatility.

A Little Company Context

Remember, Twist Bioscience is in the Healthcare sector, specifically Diagnostics & Research. They make synthetic DNA products. This is a high-tech, often volatile space. The company isn't profitable yet (that's what the negative P/E ratio tells us), which is common for growth companies in this field, but it means their stock price can react strongly to news about their technology, sales, or the broader biotech market. They're a mid-size company with a market cap around $2.3 billion.

Important Disclaimer: This analysis is purely for informational purposes based on the provided data. It's not financial advice. Stock markets are risky, and prices can go down as well as up. Always do your own thorough research or talk to a qualified financial advisor before making any investment decisions.

相關新聞

BusinessWire

Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System

Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing, RNA sequencing, deep sequencing for liquid biopsy research and MRD, and methylation detection Diverse portfolio of adapter sets

查看更多
Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System
Analyst Upgrades

Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $45

Barclays analyst Luke Sergott maintains Twist Bioscience with a Overweight and lowers the price target from $58 to $45.

查看更多
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $45

AI預測Beta

AI推薦

看漲

更新於: 2025年4月28日 上午10:04

看跌中立看漲

65.9% 信心度

風險與交易

風險級別3/5
中等風險
適合
價值成長積極
交易指南

入場點

$40.24

獲利了結

$44.00

止損

$36.14

關鍵因素

DMI 顯示熊市趨勢 (ADX:13.6, +DI:11.7, -DI:12.7),建議謹慎
當前價格非常接近支撐位 ($40.18),表明強勁的買入機會
交易量是平均值 (13,325) 的 4.3 倍,表明極強的買入壓力
MACD -0.0266 在信號線 0.0231 下方,表示看跌交叉

保持更新

設定價格提醒,獲取AI分析更新和即時市場新聞。